Prostaglandin E₂-d₄

Prostaglandin E₂-d₄ (PGE₂-d₄) contains four deuterium atoms at the 3, 3', 4, and 4' positions. It is intended for use as an internal standard for the quantification of PGE₂ by GC- or LC-mass spectrometry. PGE₂ is one of the primary cyclooxygenase products of arachidonic acid and one of the most widely investigated prostaglandins. Its activity influences inflammation, fertility and parturition, gastric mucosal integrity, and immune modulation.^1,2,3,4 The effects of PGE₂ are transduced by at least four distinct receptors designated EP₁, EP₂, EP₃, and EP₄.⁵ The affinity constants (K_d) of PGE₂ for these receptors range from 1-10 nM depending on the receptor subtype and tissue.

WARNING This product is not for human or veterinary use.

1. Willis, A.L., and Cornelsen, M. Repeated injection of prostaglandin E₂ in rat paws induces chronic swelling and a marked decrease in pain threshold. Prostaglandins 3(3), 353-357 (1973).

2. Jackson, G.M., Sharp, H.T., and Varner, M.W. Cervical ripening before induction of labor: A randomized trial of prostaglandin E₂ gel versus low-dose oxytocin. Am. J. Obstet. Gynecol. 171(4), 1092-1096 (1994).

3. Robert, A., Schultz, J.R., Nezamis, J.E., et al. Gastric antisecretory and antiulcer properties of PGE₂, 15-methyl PGE₂, and 16,16-dimethyl PGE₂. Intravenous, oral and intrajejunal administration. Gastroenterology 70(3), 359-370 (1976).

4. Arvind, P., Papavassiliou, E.D., Tsioulias, G.J., et al. Prostaglandin E₂ down-regulates the expression of HLA-DR antigen in human colon adenocarcinoma cell lines. Biochemistry 34(16), 5604-5609 (1995).

5. Coleman, R.A., Smith, W.L., and Narumiya, S. International Union of Pharmacology classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes. Pharmacol. Rev. 46(2), 205-229 (1994).

Wu, Z., Xiao, H., Rao, D., et al. Analytical strategy for oxylipin annotation by combining chemical derivatization-based retention index algorithm and feature tandem mass spectrometric fragmentation as a biomarker discovery tool. Anal. Chem. 95(43), 15933-15942 (2023).

Archambault, A.-S., Brassard, J., Bernatchez, É., et al. Human and mouse eosinophils differ in their ability to biosynthesize eicosanoids, docosanoids, the endocannabinoid 2-arachidonoyl-glycerol and its congeners. Cells 11(1), 141 (2022).

Roberts, L.M., Schwarz, B., Speranza, E., et al. Pulmonary infection induces persistent, pathogen-specific lipidomic changes influencing trained immunity. iScience 24(9), 103025 (2021).

Roulis, M., Kaklamanos, A., Schernthanner, M., et al. Paracrine orchestration of intestinal tumorigenesis by a mesenchymal niche. Nature 580(7804), 524-529 (2020).

Archambault, A.-S., Zaid, Y., Rakotoarivelo, V., et al. Lipid storm within the lungs of severe COVID-19 patients: Extensive levels of cyclooxygenase and lipoxygenase-derived inflammatory metabolites. medRxiv (2020).

Brouwers, H., Jónasdóttir, H.S., Kuipers, M.E., et al. Anti-inflammatory and proresolving effects of the omega-6 polyunsaturated fatty acid adrenic acid. J. Immunol. 205(10), 2840-2849 (2020).

Meriwether, D., Sulaiman, D., Volpe, C., et al. Apolipoprotein A-I mimetics mitigate intestinal inflammation in COX2-dependent inflammatory bowel disease model. J. Clin. Invest. 130, 3670-3685 (2019).

Norris, P.C., Libreros, S., and Serhan, C.N. Resolution metabolomes activated by hypoxic environment. Sci. Adv. 5(10), eaax4895 (2019).

Maric, J., Ravindran, A., Mazzurana, L., et al. Cytokine-induced endogenous production of prostaglandin D₂ is essential for human group 2 innate lymphoid cell activation. J. Allergy Clin. Immunol. 143(6), 2202-2214 (2019).

Naoe, S., Tsugawa, H., Takahashi, M., et al. Characterization of lipid profiles after dietary intake of polyunsaturated fatty acids using integrated untargeted and targeted lipidomics. Metabolites 9(10), 241 (2019).

Dalli, J., Colas, R.A., Walker, M.E., et al. Lipid Mediator Metabolomics via LC-MS/MS Profiling and Analysis. Clinical Metabolomics 59-72 (2018).

Sorgi, C.A., Peti, A.P.F., Petta, T., et al. Comprehensive high-resolution multiple-reaction monitoring mass spectrometry for targeted eicosanoid assays. Sci. Data 5, 180167 (2018).

Lin, N., Shay, J.E.S., Xie, H., et al. Myeloid cell hypoxia-inducible factors promote resolution of inflammation in experimental colitis. Front. Immunol. 9(2565), (2018).

English, J.T., Norris, P.C., Hodges, R.R., et al. Identification and profiling of specialized pro-resolving mediators in human tears by lipid mediator metabolomics. Prostaglandins Leukot. Essent. Fatty Acids 117, 17-27 (2017).

Parker, C.G., Galmozzi, A., Wang, Y., et al. Ligand and target discovery by fragment-based screening in human cells. Cell 168(3), 527-541.e529 (2017).

Gouveia-Figueira, S., Karlsson, J., Deplano, A., et al. Characterisation of (R)-2-(2-fluorobiphenyl-4-yl)-N-(3-methylpyridin-2-yl)propanamide as a dual fatty acid amide hydrolase: Cyclooxygenase inhibitor. PLoS One 10(9), e0139212 (2015).

Sasaki, A., Fukuda, H., Shiida, N., et al. Determination of ω-6 and ω-3 PUFA metabolites in human urine samples using UPLC/MS/MS. Anal. Bioanal. Chem. 407(6), 1625-1639 (2015).

Rouzer, C.A., and Marnett, L.J. Glycerylprostaglandin synthesis by resident peritoneal macrophages in response to a zymosan stimulus. The Journal of Biological Chemisty 280(29), 26690-26700 (2005).

Sakairi, Y., Jacobson, H.R., Noland, T.D., et al. 5,6-EET inhibits ion transport in collecting duct by stimulating endogenous prostaglandin synthesis. Am. J. Physiol. 268(5 Pt 2), F931-F939 (1995).